Month: June 2020

SUNNYVALE, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Ooma, Inc., a smart communications platform for businesses and consumers, today announced the appointment of Judi Hand, an experienced cloud services sales and marketing leader, to its board of directors, effective June 3, 2020.Hand is executive vice president and chief revenue officer of TTEC Holdings in Englewood, Colorado, a global customer experience technology and services company serving many of the world’s most iconic and disruptive brands, with 48,700 employees on six continents. With more than 25 years of sales and marketing experience, Hand has held senior positions at telecom industry leaders including AT&T, Northwestern Bell, US West and Qwest.From 2014 to 2017, Hand was an independent board member at Manitoba Telecom Services / Allstream. Hand holds an M.S. degree...

DUBLIN, Ireland, June 08, 2020 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced that Greg Divis, Chief Executive Officer of Avadel, and Jordan Dubow, M.D., Chief Medical Officer of Avadel, will present a corporate overview at BIO Digital from June 8-12, 2020.The presentation will focus on the development of once-nightly FT218 and positive results from the Phase 3 Rest-On clinical trial. The presentation will be available on-demand during the conference via https://www.bio.org/events/bio-digital/sessions/693802.About Avadel Pharmaceuticals plc:Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company....

ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020, at 4:40 p.m. Eastern Time.A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/. Replay of the webcast will be archived on the Company’s website for 90 days following the event.Esperion TherapeuticsThrough scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact...

SAN JOSE, June 08, 2020 (GLOBE NEWSWIRE) — Andes Technology Corporation (TWSE: 6533), a leading supplier of high efficiency, low-power 32/64-bit RISC-V processor cores and founding member of RISC-V International, announces its Premier membership in the organization. Andes President Frankwell Lin takes his seat on the RISC-V International Board. Andes CTO and Executive VP Charlie Su becomes Vice Chair of  the RISC-V International Technical Steering Committee. The company will take an active role in the upcoming 2020 RISC-V Summit. Andes’ increased participation in RISC-V International reflects the growing demand for its broad family of RISC-V cores including its highly demanded RISC-V cores with DSP or vector extensions. As a result, Andes Technology is growing its U.S. footprint by expanding its R&D and applications engineering...

DEERFIELD, Ill., June 08, 2020 (GLOBE NEWSWIRE) — RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced that it has completed the filing of its 2019 Form 10-K and has completed its previously announced financial statement restatement.The Company has also completed its previously announced internal investigation of certain accounting matters, including the Company’s revenue recognition practices for certain contractual arrangements, primarily with OEM customers involving the accounting treatment, financial reporting and internal controls related to such arrangements. The Company revised its financial statements to correct for errors, and has filed restated audited consolidated financial statements for the fiscal years ended December 31, 2016, 2017 and 2018, selected financial data for the...

HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced the presentation of 28-day clinical outcomes data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation at the European E-Congress of Rheumatology (EULAR) 2020. The company also announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for its global placebo-controlled Phase 2/3...

INDIANAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the second fiscal quarter ended April 30, 2020. Hurco recorded a net loss of $3,927,000, or $(0.58) per diluted share, for the second quarter of fiscal 2020, compared to net income of $5,252,000, or $0.76 per diluted share, for the corresponding period in fiscal 2019. For the first six months of fiscal 2020, Hurco reported a net loss of $4,820,000, or $(0.71) per diluted share, compared to net income of $11,906,000, or $1.73 per diluted share, for the corresponding period in fiscal 2019.Sales and service fees for the second quarter of fiscal 2020 were $37,126,000, a decrease of $33,548,000, or 47%, compared to the corresponding prior year period, and included an unfavorable currency impact of $438,000, or less than 1%,...

MINNEAPOLIS, June 08, 2020 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Phil Ebeling as Chief Operating Officer. Mr. Ebeling is an accomplished global healthcare executive with broad experience in product innovation, strategic planning and business development. In this newly created role at Inspire, he will be responsible for the oversight and leadership of operations, quality assurance, clinical research, regulatory affairs, and business development activities.“At Inspire, we continue to accelerate our growth even during these challenging times. As such, it is imperative that we have the optimal...

RICHMOND, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,747,704 of its shares of common stock, at a purchase price of $4.5145 per share, in a registered direct offering priced at-the-market under Nasdaq Rules. The Company has also agreed to issue to the investors in a concurrent private placement warrants to purchase up to an aggregate of 873,852 shares of common stock. The closing of the offering is expected to occur on or about June 10, 2020, subject to the satisfaction of customary closing conditions.Ekso Bionics® is a leading developer...

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce  that its wholly-owned subsidiary Blueberries SAS entered into a collaboration agreement (the “Partnership“) with Medicanmentos de Cannabis SAS (“medcann”), to develop, and produce Tetrahydrocannabinol (“THC”) cannabis extracts for the international market.Blueberries will develop a Research and Development (“R&D”) project with medcann to produce commercial THC dominant extracts. The Company will utilize its extraction capabilities to process the THC dominant cannabis flower cultivated by medcann. In 2018, medcann became the first and only company to obtain...